Skip to main content
Erschienen in: International Urogynecology Journal 11/2017

20.04.2017 | Original Article

Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence

verfasst von: Kirill Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Natalya Zhuravskaya, Alexandra Lobodenko

Erschienen in: International Urogynecology Journal | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Aim

Our aim was to determine the efficiency of the Medication Compliance Self-Report Inventory (MASRI) in self-reporting antimuscarinic drug treatment compliance among women with urinary incontinence (UI).

Materials and methods

The study assessed 347 women aged 18–65 (averaging 49.7) years with more than one urinary incontinence (UI) episode per day. Treatment compliance was tested at the beginning and at weeks 4, 8, and 12 using the MASRI, the Brief Medication Questionnaire (BMQ), and visual pill counts. The MASRI’s constructive, concurrent, and discriminate validity was studied in comparison with an external standard that uses the chi-square and Spearman coefficient. Receiver operating characteristic (ROC) analysis was performed to identify optimum MASRI cutoffs that would predict noncompliance. Furthermore, the functional condition of the lower urinary tract was tested using voiding diaries, uroflowmetry, and cystometry.

Result

The correlation between the percentage of noncompliant women according to the MASRI, and individuals with a belief barrier with respect to the BMQ screen was r = 0.81 (p ≤0.05), r = 0.84 (p ≤0.05), and r = 0.79 (p ≤0.05). The correlation between the percentage of noncompliant women according to the MASRI and of women who missed >20% of their doses according to the Regimen Screen of the BMQ was r = 0.79, p ≤0.05, r = 0.82, p ≤0.01, r = 0.77, and p ≤0.05 at the control points. Finally, the percentage of noncompliant patients who self-reported correctly according to the MASRI data compared with the BMQ was 95.6%, 95.7%, and 96.6% at the control points.

Conclusion

The MASRI entails acceptable validity for accurately predicting treatment compliance with antimuscarinic drugs among women who have had UI for >3 months.
Literatur
1.
Zurück zum Zitat Sensoy N, Dogan N, Ozek B, Karaaslan L. Urinary incontinence in women: prevalence rates, risk factors and impact on quality of life. Pak J Med Sci. 2013;29(3):818–22.CrossRefPubMedPubMedCentral Sensoy N, Dogan N, Ozek B, Karaaslan L. Urinary incontinence in women: prevalence rates, risk factors and impact on quality of life. Pak J Med Sci. 2013;29(3):818–22.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Abrams P, Andersson KE, Birder L. Fourth International consultation on incontinence recommendations of the International scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.CrossRefPubMed Abrams P, Andersson KE, Birder L. Fourth International consultation on incontinence recommendations of the International scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.CrossRefPubMed
3.
Zurück zum Zitat Coyne KS, Sexton CC, Bell JA, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.CrossRefPubMed Coyne KS, Sexton CC, Bell JA, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.CrossRefPubMed
4.
Zurück zum Zitat Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–63.CrossRefPubMed Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–63.CrossRefPubMed
5.
Zurück zum Zitat Kogan MI, Zachoval R, Ozyurt C, Schäfer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014;30(10):2119–30.CrossRefPubMed Kogan MI, Zachoval R, Ozyurt C, Schäfer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014;30(10):2119–30.CrossRefPubMed
6.
Zurück zum Zitat Sexton CC, Coyne KS, Vats V, Koppz S, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.PubMed Sexton CC, Coyne KS, Vats V, Koppz S, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.PubMed
7.
Zurück zum Zitat Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida M. Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. Eur J Obstet Gynecol Reprod Biol. 2014;174:27–34.CrossRefPubMed Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida M. Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. Eur J Obstet Gynecol Reprod Biol. 2014;174:27–34.CrossRefPubMed
8.
Zurück zum Zitat Erdem N, Chu F. Management of overactive bladder disease and urge urinary incontinence in the elderly patient. Am J Med. 2006;119:29–36.CrossRefPubMed Erdem N, Chu F. Management of overactive bladder disease and urge urinary incontinence in the elderly patient. Am J Med. 2006;119:29–36.CrossRefPubMed
9.
Zurück zum Zitat Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861–74. W301-10CrossRefPubMed Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861–74. W301-10CrossRefPubMed
10.
Zurück zum Zitat Kosilov K, Loparev S, Ivanovskaya M. Liliya Kosilova maintenance of the therapeutic effect of two high-dosage Antimuscarinics in the Management of Overactive Bladder in elderly women. Int Neurourol J. 2013;17(4):191–6.CrossRefPubMedPubMedCentral Kosilov K, Loparev S, Ivanovskaya M. Liliya Kosilova maintenance of the therapeutic effect of two high-dosage Antimuscarinics in the Management of Overactive Bladder in elderly women. Int Neurourol J. 2013;17(4):191–6.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent Eur J Urol. 2014;01. art. 9, 43–48 Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent Eur J Urol. 2014;01. art. 9, 43–48
12.
Zurück zum Zitat Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect. Int J Urol Nurs. 2015;9(2):108–13.CrossRef Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect. Int J Urol Nurs. 2015;9(2):108–13.CrossRef
13.
Zurück zum Zitat Andy UU, Harvie HS, Smith AL, Propert KJ, Bogner HR, Arya LA. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn. 2015;34(5):424–8.CrossRefPubMed Andy UU, Harvie HS, Smith AL, Propert KJ, Bogner HR, Arya LA. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn. 2015;34(5):424–8.CrossRefPubMed
14.
Zurück zum Zitat Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112(6):1311–8.CrossRefPubMed Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112(6):1311–8.CrossRefPubMed
15.
Zurück zum Zitat Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, Kirby M, Milsom I, Vierhout M, Van Kerrebroeck P, Kelleher C. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.CrossRefPubMed Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, Kirby M, Milsom I, Vierhout M, Van Kerrebroeck P, Kelleher C. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.CrossRefPubMed
16.
Zurück zum Zitat Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.CrossRefPubMed Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.CrossRefPubMed
17.
Zurück zum Zitat Farmer KC. Medication adherence in health care: are we utilizing what we have learned? Clin Ther. 2011;33(8):1081–3.CrossRefPubMed Farmer KC. Medication adherence in health care: are we utilizing what we have learned? Clin Ther. 2011;33(8):1081–3.CrossRefPubMed
18.
Zurück zum Zitat Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, Passo MH, Houk JL, Higgins GC, Brunner HI. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007;57(6):1000–6.CrossRefPubMed Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, Passo MH, Houk JL, Higgins GC, Brunner HI. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007;57(6):1000–6.CrossRefPubMed
19.
Zurück zum Zitat Chapple CR, Drake MJ, Van Kerrebroeck P, Cardozo L, et al. Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int. 2014;113(5):696–703.CrossRefPubMed Chapple CR, Drake MJ, Van Kerrebroeck P, Cardozo L, et al. Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int. 2014;113(5):696–703.CrossRefPubMed
20.
Zurück zum Zitat Amundsen CL, Parsons M, Cardozo L, Vella M, Webster GD, Coats AC. Bladder diary volume per void measurements in detrusor overactivity. J Urol. 2006;176(6 Pt. 1):2530–4.CrossRefPubMed Amundsen CL, Parsons M, Cardozo L, Vella M, Webster GD, Coats AC. Bladder diary volume per void measurements in detrusor overactivity. J Urol. 2006;176(6 Pt. 1):2530–4.CrossRefPubMed
21.
Zurück zum Zitat Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson P. Minimum standards for urodynamic practice in the UK. Neurol Urodyn. 2010;29(8):1365–72.CrossRef Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson P. Minimum standards for urodynamic practice in the UK. Neurol Urodyn. 2010;29(8):1365–72.CrossRef
22.
Zurück zum Zitat Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–24.CrossRefPubMed Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–24.CrossRefPubMed
23.
Zurück zum Zitat Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007;3(4):363–77.CrossRefPubMed Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007;3(4):363–77.CrossRefPubMed
24.
Zurück zum Zitat Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.CrossRefPubMed Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.CrossRefPubMed
25.
Zurück zum Zitat Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85.CrossRefPubMed Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85.CrossRefPubMed
26.
Zurück zum Zitat Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624–32.CrossRefPubMed Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624–32.CrossRefPubMed
27.
Zurück zum Zitat Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011;51:90–4.CrossRef Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011;51:90–4.CrossRef
28.
Zurück zum Zitat Deeks JJ, Altman DG. Diagnostic Tests 4: Likelihood Ratios. BMJ. 2004;329:168–169. Deeks JJ, Altman DG. Diagnostic Tests 4: Likelihood Ratios. BMJ. 2004;329:168–169.
29.
Zurück zum Zitat Kosilov K, Loparev S, Ivanovskaya 440 M, Kosilova L. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Therapeutic Advances in Urology. December 2014;6:215–223. Kosilov K, Loparev S, Ivanovskaya 440 M, Kosilova L. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Therapeutic Advances in Urology. December 2014;6:215–223.
Metadaten
Titel
Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence
verfasst von
Kirill Kosilov
Sergey Loparev
Irina Kuzina
Olga Shakirova
Natalya Zhuravskaya
Alexandra Lobodenko
Publikationsdatum
20.04.2017
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 11/2017
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-017-3333-4

Weitere Artikel der Ausgabe 11/2017

International Urogynecology Journal 11/2017 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.